{
    "nct_id": "NCT04205812",
    "official_title": "A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)",
    "inclusion_criteria": "* Histologically or cytologically confirmed NSCLC (either nonsquamous or squamous) that is Stage IV (AJCC v8).\n* No prior systemic treatment for the advanced/metastatic NSCLC\n* Able to provide a formalin-fixed archival tumor tissue sample during screening, or a fresh tumor biopsy\n* Measurable disease per RECIST v1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy of at least 3 months.\n* Willingness to avoid pregnancy or fathering children.\n* Adequate organ function as indicated by protocol-specified laboratory values. - Has been fully vaccinated against SARS-CoV-2 or is willing and able to be fully vaccinated against SARS-CoV-2 during the study by starting the vaccination process during screening.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Clinically significant cardiac disease within 6 months of start of study treatment.\n* Any major surgery within 3 weeks of the first dose of study treatment.\n* Thoracic radiation therapy of > 30 Gy within 6 months of the first dose of study treatment.\n* History of peripheral neuropathy ≥ Grade 2 CTCAE v5 for participants who may receive cisplatin, paclitaxel, or nab-paclitaxel.\n* Untreated central nervous system metastases and/or carcinomatous meningitis.\n* Evidence or history of interstitial lung disease or noninfectious pneumonitis that required systemic steroids.\n* Active infection requiring systemic therapy or active tuberculosis. Note: If required by country or local regulations to be tested for COVID-19 during screening, a participant should be excluded if they have a positive test result for SARS CoV-2 infection until both the retesting result is negative and clinical recovery is obtained.\n* Superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.\n* Has contraindications to chemotherapy agents used in the study.\n* Has an active autoimmune disease that has required systemic treatment in past 2 years.\n* Is receiving systemic antibiotics or steroid therapy ≤ 7 days prior to the first dose of study treatment.\n* Has received a live vaccine within 30 days before the first dose of study treatment (and until 90 days after last dose of study drug).\n\nNote: While based on approved SARS-CoV-2 vaccines available worldwide, many vaccines are not live (mRNA and adenovirus vaccines do not contain live virus), if a live vaccine against SARS-CoV-2 is the only available option, prior consultation with the medical monitor should be obtained.\n\n• Has known active HBV or HCV (testing must be performed to determine eligibility)",
    "miscellaneous_criteria": ""
}